Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
SynAct Pharma AB
AB
Active
Org 5590584826
Scheelevägen 2, 223 63
Lund
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2016 · 10 years old
1-4 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
SynAct Pharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
10M
7M
5M
2M
0M
2021: 2M
2M
2021
2022: 5M (+150% vs 2021)
5M
+150%
2022
2023: 8M (+60% vs 2022)
8M
+60%
2023
2024: 7M (-12% vs 2023)
7M
-12%
2024
2025: 7M (0% vs 2024)
7M
0%
2025
EBITDA
SEK millions
0M
-7M
-14M
-21M
-29M
2021: -11M
-11M
2021
2022: -21M (-91% vs 2021)
-21M
-91%
2022
2023: -23M (-10% vs 2022)
-23M
-10%
2023
2024: -22M (+4% vs 2023)
-22M
+4%
2024
2025: -13M (+41% vs 2024)
-13M
+41%
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
6 839
6 969
8 262
5 144
1 637
Staff expenses
—
—
—
—
—
EBITDA
−13 115
−22 359
−23 018
−20 671
−10 962
Depreciation & amort.
—
—
—
—
−0
EBIT
−13 115
−22 359
−23 018
−20 671
−10 962
Net financials
−85 030
−70 310
−126 510
−111 420
−50 010
Profit before tax
−98 144
−90 623
−149 529
−130 970
−60 966
Tax
−0
−0
−0
−0
−0
Net profit
−98 144
−90 623
−149 529
−130 970
−60 966
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
230 217
257 757
230 768
119 225
45 334
Equity
216 293
241 360
214 072
111 127
40 404
Long-term debt
10 606
8 304
8 821
0
0
Short-term debt
3 318
8 093
7 876
8 098
4 930
Total debt
13 924
16 397
16 697
8 098
4 930
Financial ratios
5-year trend
EBITDA margin
−191,8 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2021
2025
Equity ratio
94,0 %
This company
38,2 %
Market median
This company
Market median
146% above market
2021
2025
Return on equity
−45,4 %
This company
18,4 %
Market median
This company
Market median
347% below market
2021
2025
Net profit margin
<−999 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2021
2025
Asset turnover
0,03×
This company
1,12×
Market median
This company
Market median
97% below market
2021
2025
Debt / equity
0,06×
This company
0,62×
Market median
This company
Market median
90% below market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on SynAct Pharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
